Volume 10 Supplement 2
Familial Aspects of Cancer 2011 Research and Practice
Meeting abstracts
Edited by Rodney Scott
Familial Aspects of Cancer 2011 Research and Practice: A combined meeting of kConFab, Australian Breast Cancer Family Study, Australian Colorectal Cancer Family Study, Australian Ovarian Cancer Study, Family Cancer Clinics of Australia and New Zealand and kConFab.
Kingscliff, Australia23-26 August 2011
Page 1 of 2
-
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A2
-
Inherited and de novo germline TP53 mutations in adult-onset sarcoma
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A3 -
I just did it for the kids: mothering in the context of living with an increased risk of ovarian cancer
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A4 -
Are women at high risk for serous gynaecological cancer (SGC) opting for risk-reducing salphingo-oophorectomy motivated by high levels of anxiety and risk perceptions?
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A5 -
Rehabilitating the sick role: post-surgical experiences of high risk women who undergo risk reducing mastectomy
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A6 -
Use of SDHB immunohistochemistry to identify germline mutations of SDH genes
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A7 -
Dissecting genetic pathways in schwannomatosis and malignant rhabdoid tumour
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A8 -
An update of clinical issues from InSIGHT 2011
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A9 -
Selecting women for breast cancer chemoprevention and what agents should be used
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A10 -
Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A11 -
Bowel cancer chemoprevention - ready for the clinic?
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A12 -
Risk-reducing surgery for breast and ovarian cancer risks - where are we now?
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A13 -
"It's not even about her it's about the whole family": accounts of participation in a family cancer study
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A14 -
The experiences of research participants offered genetic test results as a result of taking part in a population based ovarian cancer research study?
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A15 -
Peer live supervision in the familial cancer setting
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A16 -
Looking for RED FLAGS: identifying and supporting patients at risk of adverse psychological responses to genetic counselling and testing
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A17 -
A state-wide population-based program for detection of Lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A18 -
Hyperplastic polyposis syndrome: endoscopic imaging, phenotypic charcteristics and molecular pathways
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A19 -
Serrated polyposis syndrome and colonoscopic surveillance: who is it safe to follow?
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A20 -
A study of cancer risks in relatives of patients with serrated polyposis
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A21 -
Mismatch repair gene mutations and cancer risks: an update
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A22 -
The relationship between the BRAF p.V600E mutation and a family history of CRC in the early-onset CRC cases from the Australasian Colon Cancer Family Study
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A23 -
Targeting oncogenes in advanced melanoma
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A24 -
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A25 -
Inherited and de novo germline TP53 mutations in adult-onset sarcoma
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A26 -
A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A27 -
Common genomic variants associated with breast cancer predict the risk of second primary breast cancer diagnosis
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A28 -
A breast cancer prediction model incorporating familial and personal risk factors
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A29 -
A genetic journey through cancer: from rarity and family to aspirin and nanowires
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A30 -
Estimation of probabilities in favour of pathogenicity for missense substitutions for use in clinical evaluation of mismatch repair gene variants
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A31 -
Chromosome 8q23.3, 10p14 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome – a combined analysis of the Australian, Dutch and Polish Lynch syndrome cohorts
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A32 -
Substantial unexplained variation in cancer risks for MLH1 and MSH2 mutation carriers
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A33 -
OPCML, a novel systems regulator of tyrosine kinase signaling in ovarian and other cancers
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A34 -
Reclassifying ovarian cancer: origins, subtypes and resistance to therapy
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A35 -
Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A36 -
Expression of genes involved in DNA repair and cell cycle checkpoint pathways in Triple Negative compared to Luminal A Breast Cancer: a molecular characterization
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A37 -
Design considerations for massively parallel sequencing studies of common familial cancers
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A38 -
Whole genome sequencing in the study of disease and application in personalised medicine
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A39 -
Identification of new breast cancer predisposition genes via whole exome sequencing
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A40 -
Identification of breast cancer susceptibility genes using whole exome sequencing
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A41 -
An audit of families with unreported or misreported cancers verified through a population-based cancer registry: implications for providing cancer risk assessment and management advice by a Familial Cancer Centre
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A42 -
When is it best to test? Attitudes of health professionals regarding genetic testing for Familial Adenomatous Polyposis (FAP)
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A43 -
Clinical practice improvement in the genetics clinic
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A44 -
Is the whole greater than the sum of its parts?
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A45 -
From GWAS to genome sequencing: complementary approaches to identify melanoma predisposition genes
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A46 -
A genome-wide association study to identify genetic markers associated with endometrial cancer grade
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A47 -
‘Next-generation’ genome wide association studies
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A48 -
An audit of treatment focussed BRCA1/2 mutation testing at an integrated Familial Cancer Clinic
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A49 -
Audit of adherence to GI screening recommendations for Lynch Syndrome Patients
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A50 -
Observation of the cancer patient journey: a learning curve for Genetic Counsellors
Citation: Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A51
Follow
Annual Journal Metrics
-
Citation Impact
2.164 - 2-year Impact Factor (2021)
2.089 - 5-year Impact Factor (2021)
0.850 - Source Normalized Impact per Paper (SNIP)
0.546 - SCImago Journal Rank (SJR)Speed
44 days to first decision for all manuscripts (Median)
62 days to first decision for reviewed manuscripts only (Median)Usage
277,857 Downloads (2022)
133 Altmetric mentions (2021)